Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099367 | 0.90 | MEN1 (0.46) | POLBMEN1KMT2AAPAF1ALDH1A1 | |
| SCHEMBL7098427 | 0.89 | MEN1 (0.46) | POLBMEN1KMT2AAPAF1ALDH1A1 | |
| SCHEMBL7153122 | 0.88 | MEN1 (0.45) | POLBMEN1KMT2AAPAF1ALDH1A1 | |
| SCHEMBL6631891 | 0.87 | MEN1 (0.46) | POLBMEN1KMT2AAPAF1ALDH1A1 | |
| SCHEMBL7101207 | 0.84 | KMT2A (0.58) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL7123940 | 0.83 | MEN1 (0.44) | POLBMEN1KMT2AAPAF1ALDH1A1 | |
| SCHEMBL7097929 | 0.82 | MEN1 (0.44) | POLBMEN1KMT2APDE4DAPAF1 | |
| SCHEMBL13261760 | 0.79 | MEN1 (0.44) | POLBMEN1KMT2AAPAF1ALDH1A1 | |
| SCHEMBL6630866 | 0.78 | CA12 (0.58) | MEN1KMT2APDE4DAPAF1ALDH1A1 | |
| SCHEMBL7102777 | 0.74 | MEN1 (0.43) | POLBMEN1KMT2AAPAF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670383-B2 | Such as 5-(2-hydroxy-ethoxy)-2,2-dimethyl-6-propionyl-10-propyl-2H-pyrano(2,3 -f)chromen-8-one for treatment of Mycobacterium infection, AIDS, and tuburculosis | ADVANCED LIFE SCIENCES, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030083369-A1 | Pyranocoumarin compounds as a novel pharmacophore with anti-TB activity | THE LEADERS BANK | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083369-A1 | Pyranocoumarin compounds as a novel pharmacophore with anti-TB activity | BBOX1, CYP51A1, HADHB | POLB 1031/4885MEN1 4150/4885KMT2A 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.